SARS‐CoV‐2 B.1.1.7 reinfection after previous COVID‐19 in two immunocompetent Italian patients

Novazzi, Federica; Baj, Andreina; Genoni, Angelo; Spezia, Pietro Giorgio; Colombo, Alberto; Cassani, Gianluca; Zago, Cristian; Pasciuta, Renée; Gasperina, Daniela Dalla; Ageno, Walter; Severgnini, Paolo; Dentali, Francesco; Focosi, Daniele; Maggi, Fabrizio

doi:10.1002/jmv.27066

Cited by 11 publications

(12 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Seven patients died (aged 44-92): one died of septic shock and respiratory failure [10], another one died of respiratory failure [77], and the cause of death was not reported for the remaining five patients [43,44,54,75]. Five patients were reported as still being hospitalized [38,41,61], and five patients had been discharged from hospital [35,42,52,66].…”

Section: Patient Outcomesmentioning

confidence: 99%

Reinfection in patients with COVID-19: a systematic review

Ren

Zhou

Guo

et al. 2022

glob health res policy

View full text Add to dashboard Cite

Background With the continuation of the COVID-19 pandemic, some COVID-19 patients have become reinfected with the virus. Viral gene sequencing has found that some of these patients were reinfected by the different and others by same strains. This has raised concerns about the effectiveness of immunity after infection and the reliability of vaccines. To this end, we conducted a systematic review to assess the characteristics of patients with reinfection and possible causes. Methods A systematic search was conducted across eight databases: PubMed, Embase, Web of Science, The Cochrane Library, CNKI, WanFang, VIP and SinoMed from December 1, 2019 to September 1, 2021. The quality of included studies were assessed using JBI critical appraisal tools and Newcastle–Ottawa Scale. Results This study included 50 studies from 20 countries. There were 118 cases of reinfection. Twenty-five patients were reported to have at least one complication. The shortest duration between the first infection and reinfection was 19 days and the longest was 293 days. During the first infection and reinfection, cough (51.6% and 43.9%) and fever (50% and 30.3%) were the most common symptoms respectively. Nine patients recovered, seven patients died, and five patients were hospitalized, but 97 patients’ prognosis were unknown. B.1 is the most common variant strain at the first infection. B.1.1.7, B.1.128 and B.1.351 were the most common variant strains at reinfection. Thirty-three patients were infected by different strains and 9 patients were reported as being infected with the same strain. Conclusions Our research shows that it is possible for rehabilitated patients to be reinfected by SARS-COV-2. To date, the causes and risk factors of COVID-19 reinfection are not fully understood. For patients with reinfection, the diagnosis and management should be consistent with the treatment of the first infection. The public, including rehabilitated patients, should be fully vaccinated, wear masks in public places, and pay attention to maintaining social distance to avoid reinfection with the virus.

show abstract

Section: Patient Outcomesmentioning

confidence: 99%

Reinfection in patients with COVID-19: a systematic review

Ren

Zhou

Guo

et al. 2022

glob health res policy

View full text Add to dashboard Cite

show abstract

“…Immune responses to SARS-CoV-2 reach to peak levels within 1–4 weeks after infection or vaccination and persist within 3–8 months. 47–50 Novazzi et al 51 reported that two patients naturally infected with Alpha were reinfected with the same variant after 45–90 days. Loconsole et al 52 reported that medical workers who received two doses of the BNT162b2 vaccine developed breakthrough infections, and their serum had high titers of specific IgG against the Alpha variant at the time of diagnosis.…”

Section: Introduction To Vocs Designated By the Whomentioning

confidence: 99%

Research progress on vaccine efficacy against SARS-CoV-2 variants of concern

Bian

Liu

Gao

et al. 2022

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to circulate worldwide and a variety of variants have emerged. Variants of concern (VOC) designated by the World Health Organization (WHO) have triggered epidemic waves due to their strong infectivity or pathogenicity and potential immune escape, among other reasons. Although large-scale vaccination campaigns undertaken globally have contributed to the improved control of SARS-CoV-2, the efficacies of current vaccines against VOCs have declined to various degrees. In particular, the highly infectious Delta and Omicron variants have caused recent epidemics and prompted concerns about control measures. This review summarizes current VOCs, the protective efficacy of vaccines against VOCs, and the shortcomings in methods for evaluating vaccine efficacy. In addition, strategies for responding to variants are proposed for future epidemic prevention and control as well as for vaccine research and development.

show abstract

“…Guidelines do not currently advise specific cohorting ( 24 ), but it has been successfully implemented in some Canadian institutions ( 25 ). Repeat infections with VOC (B.1.1.7, P.1, and B.1.351) have been reported in patients previously infected with SARS-CoV-2 ( 26 ). Cohorting may be an adjunct infection control measure considered in certain clinical situations where transmission risk is potentially higher, particularly in communities where multiple VOC are cocirculating.…”

Section: Clinical Use Cases Of Sars-cov-2 Genotypingmentioning

confidence: 96%

Clinical and Infection Prevention Applications of Severe Acute Respiratory Syndrome Coronavirus 2 Genotyping: an Infectious Diseases Society of America/American Society for Microbiology Consensus Review Document

et al. 2022

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged into a world of maturing pathogen genomics, with more than 2 million genomes sequenced at the time of writing. The rise of more transmissible variants of concern that impact vaccine and therapeutic effectiveness has led to widespread interest in SARS-CoV-2 evolution. Clinicians are also eager to take advantage of the information provided by SARS-CoV-2 genotyping beyond surveillance purposes. Here, we review the potential role of SARS-CoV-2 genotyping in clinical care. The review covers clinical use cases for SARS-CoV-2 genotyping, methods of SARS-CoV-2 genotyping, assay validation and regulatory requirements, and clinical reporting for laboratories, as well as emerging issues in clinical SARS-CoV-2 sequencing. While clinical uses of SARS-CoV-2 genotyping are currently limited, rapid technological change along with a growing ability to interpret variants in real time foretells a growing role for SARS-CoV-2 genotyping in clinical care as continuing data emerge on vaccine and therapeutic efficacy.

show abstract

SARS‐CoV‐2 B.1.1.7 reinfection after previous COVID‐19 in two immunocompetent Italian patients

Cited by 11 publications

References 6 publications

Reinfection in patients with COVID-19: a systematic review

Reinfection in patients with COVID-19: a systematic review

Research progress on vaccine efficacy against SARS-CoV-2 variants of concern

Clinical and Infection Prevention Applications of Severe Acute Respiratory Syndrome Coronavirus 2 Genotyping: an Infectious Diseases Society of America/American Society for Microbiology Consensus Review Document

Contact Info

Product

Resources

About